1-4 of 4
Paul Frohna
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of ICT01, a γ9δ2 T Cell-Activating Monoclonal Antibody, Combined with Venetoclax and Azacitidine in 1L AML (EVICTION Study)

Elisabeth Wieduwild, Anne-Charlotte Le Floch, Céline Garulli, Caroline Imbert, Aude De Gassart, Patrick Brune, Katrien Lemmens, Sylvain Garciaz, Abhishek Maiti, Pierre Peterlin, Celine Leparquier, Marina Iche, Norbert Vey, Daniel Olive, Paul Frohna
Journal: Blood
Blood (2023) 142 (Supplement 1): 1552.
https://doi.org/10.1182/blood-2023-189936
Published: 2023
Journal Articles

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Kerry Rogers, Anjali Mishra, PhD, Thomas A. Waldmann, MD, Nazli Azimi, PhD PharmD, Paul Frohna, MD PhD PharmD, Anoshie Ratnayake, MD, Thomas P Loughran, Jr., MD, Karen Ballen, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2835.
https://doi.org/10.1182/blood-2019-129291
Published: 2019
Journal Articles

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Christiane Querfeld, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Paul Frohna, MD PhD PharmD, Nazli Azimi, PhD PharmD, Jasmine M. Zain, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1557.
https://doi.org/10.1182/blood-2019-129201
Published: 2019
Journal Articles

Results from a First-in-Human Study with Bnz-1: A Novel Peptide Inhibitor of IL-2, IL-9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8 + Central Memory T-Cells

Paul Frohna, MD PhD PharmD, Yutaka Tagaya, MD PhD, Anoshie Ratnayake, MD, Nick Doerr, PhD, Asjad Basheer, PhD, Laith Al-Mawsawi, Woo Jae Kim, PhD, Juan Zapata, PhD, Xisorong Wu, BS, Nazli Azimi, PhD PharmD
Journal: Blood
Blood (2017) 130 (Supplement 1): 695.
https://doi.org/10.1182/blood.V130.Suppl_1.695.695
Published: 2017